Select Medical Holdings Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

David Chernow

Amministratore delegato

US$10.7m

Compenso totale

Percentuale dello stipendio del CEO	9.3%
Mandato del CEO	11yrs
Proprietà del CEO	0.7%
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	14.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di David Chernow rispetto agli utili di Select Medical Holdings?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$266m
Jun 30 2024	n/a	n/a	US$259m
Mar 31 2024	n/a	n/a	US$260m
Dec 31 2023	US$11m	US$995k	US$235m
Sep 30 2023	n/a	n/a	US$217m
Jun 30 2023	n/a	n/a	US$196m
Mar 31 2023	n/a	n/a	US$174m
Dec 31 2022	US$9m	US$995k	US$153m
Sep 30 2022	n/a	n/a	US$175m
Jun 30 2022	n/a	n/a	US$223m
Mar 31 2022	n/a	n/a	US$329m
Dec 31 2021	US$12m	US$995k	US$389m
Sep 30 2021	n/a	n/a	US$415m
Jun 30 2021	n/a	n/a	US$415m
Mar 31 2021	n/a	n/a	US$306m
Dec 31 2020	US$8m	US$995k	US$250m
Sep 30 2020	n/a	n/a	US$206m
Jun 30 2020	n/a	n/a	US$162m
Mar 31 2020	n/a	n/a	US$155m
Dec 31 2019	US$8m	US$995k	US$143m
Sep 30 2019	n/a	n/a	US$136m
Jun 30 2019	n/a	n/a	US$138m
Mar 31 2019	n/a	n/a	US$140m
Dec 31 2018	US$8m	US$995k	US$133m

Compensazione vs Mercato: La retribuzione totale di David ($USD 10.71M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 2.20M ).

Compensazione vs guadagni: La retribuzione di David è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

David Chernow (67 yo)

11yrs

Mandato

US$10,706,265

Compensazione

Mr. David S. Chernow serves as Director at Exokinetics, Inc. He has been the Chief Executive Officer at Select Medical Holdings Corporation and Select Medical Corporation since January 1, 2014. Mr. Chernow...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Ortenzio	Co-Founder & Executive Chairman	19.9yrs	US$10.77m	6.94% € 163.9m
David Chernow	Chief Executive Officer	11yrs	US$10.71m	0.73% € 17.2m
Michael Malatesta	Executive VP & CFO	1.3yrs	US$1.53m	0.13% € 3.1m
Michael Tarvin	Senior Executive VP	27.9yrs	US$4.44m	0.34% € 8.0m
Martin Jackson	Senior Executive Vice President of Strategic Finance & Operations	1.3yrs	US$6.47m	0.99% € 23.3m
John Saich	Co-President	1.3yrs	Nessun dato	0.51% € 12.0m
Thomas Mullin	Co-President	1.3yrs	Nessun dato	0.24% € 5.7m
Christopher Weigl	Senior VP	1.8yrs	Nessun dato	0.027% € 627.0k
Brian Rusignuolo	Executive VP & Chief Information Officer	4yrs	Nessun dato	0.23% € 5.5m
Robert Breighner	Senior Vice President of Compliance & Audit	no data	Nessun dato	0.024% € 555.7k
Shelly Eckenroth	Senior VP & Chief Communications	1.3yrs	Nessun dato	Nessun dato
Mary Lacey	Senior VP & Chief Human Resources Officer	1.3yrs	Nessun dato	Nessun dato

1.3yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di S24 non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Ortenzio	Co-Founder & Executive Chairman	19.9yrs	US$10.77m	6.94% € 163.9m
Russell Carson	Independent Lead Director	19.9yrs	US$384.40k	0.85% € 20.1m
Thomas Scully	Independent Director	20.9yrs	US$383.40k	0.069% € 1.6m
Daniel Thomas	Independent Director	5.5yrs	US$405.80k	0.051% € 1.2m
William Frist	Independent Director	14.7yrs	US$407.83k	0.22% € 5.2m
Marilyn Tavenner	Independent Director	6.2yrs	US$394.40k	0.017% € 402.9k
James Ely	Independent Director	16.2yrs	US$414.83k	0.11% € 2.7m
Katherine Davisson	Independent Director	3.8yrs	US$409.80k	0.036% € 842.1k
Parvinderjit Khanuja	Independent Director	3.2yrs	US$407.83k	0.034% € 807.2k

14.7yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di S24 è composto da personale esperto e esperto (durata media dell'incarico 14.7 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/01/20 20:05
Prezzo dell'azione a fine giornata	2025/01/20 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Select Medical Holdings Corporation è coperta da 18 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Brian Williams	Avondale Partners
Benjamin Mayo	Baird
William Sutherland	Benchmark Company

Select Medical Holdings Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Insufficient new directors

Select Medical Holdings Corporation, Annual General Meeting, Apr 25, 2024

Select Medical Holdings Corporation Announces Appointment of Michael Malatesta as Chief Financial Officer, Effective October 1, 2023

Insider recently sold €268k worth of stock

Independent Director recently sold €308k worth of stock

Recent updates

Select Medical Holdings Corporation completed the Spin-Off of Concentra Group Holdings, LLC.

Insufficient new directors

Investor sentiment improves as stock rises 16%

Third quarter dividend of US$0.13 announced

Third quarter 2024 earnings released: EPS: US$0.43 (vs US$0.38 in 3Q 2023)

Select Medical Holdings Corporation Updates Earnings Guidance for the Year Ending December 31, 2024

Select Medical Holdings Corporation to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Revenue and earnings growth

Second quarter dividend of US$0.13 announced

Second quarter 2024 earnings released: EPS: US$0.60 (vs US$0.61 in 2Q 2023)

Select Medical Holdings Corporation Declares a Cash Dividend, Payable on or About August 30, 2024

Select Medical Holdings Corporation to Report Q2, 2024 Results on Aug 01, 2024

Investor sentiment improves as stock rises 18%

First quarter dividend of US$0.13 announced

New minor risk - Shareholder dilution

First quarter 2024 earnings released: EPS: US$0.75 (vs US$0.56 in 1Q 2023)

Select Medical Reaffirms Earnings Guidance for the Year 2024

Insufficient new directors

Select Medical Holdings Corporation to Report Q1, 2024 Results on May 02, 2024

Select Medical Holdings Corporation, Annual General Meeting, Apr 25, 2024

Fourth quarter dividend of US$0.13 announced

Full year 2023 earnings released: EPS: US$1.91 (vs US$1.23 in FY 2022)

Select Medical Holdings Corporation Declares Cash Dividend, Payable on or About March 13, 2024

Select Medical Holdings Corporation to Report Q4, 2023 Results on Feb 22, 2024

Upcoming dividend of US$0.13 per share at 2.3% yield

Select Medical Holdings Corporation Declares Cash Dividend, Payable on or About November 28, 2023

Third quarter 2023 earnings released: EPS: US$0.38 (vs US$0.21 in 3Q 2022)

Select Medical Holdings Corporation to Report Q3, 2023 Results on Nov 02, 2023

Select Medical Holdings Corporation Announces Appointment of Michael Malatesta as Chief Financial Officer, Effective October 1, 2023

Select Medical Holdings Corporation Announces Cash Dividend, Payable on or about September 1, 2023

Second quarter 2023 earnings released: EPS: US$0.61 (vs US$0.43 in 2Q 2022)

Select Medical Holdings Corporation Provides Earnings Guidance for the Second Quarter Ended June 30, 2023

Select Medical Holdings Corporation to Report Q2, 2023 Results on Aug 03, 2023

Select Medical Holdings Corporation(NYSE:SEM) dropped from Russell Small Cap Comp Value Index

Insider recently sold €268k worth of stock

Upcoming dividend of US$0.13 per share at 1.7% yield

Select Medical Holdings Corporation Provides Consolidated Earnings Guidance for the Full Year of 2023

Select Medical Holdings Corporation Declares Cash Dividend, Payable on or About May 31, 2023

First quarter 2023 earnings released: EPS: US$0.56 (vs US$0.37 in 1Q 2022)

Full year 2022 earnings released: EPS: US$1.23 (vs US$2.99 in FY 2021)

Select Medical Holdings Corporation to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improved over the past week

Upcoming dividend of US$0.13 per share

Third quarter 2022 earnings released: EPS: US$0.21 (vs US$0.57 in 3Q 2021)

Select Medical Holdings Corporation Declares Cash Dividend, Payable on or About November 29, 2022

Select Medical Holdings Corporation to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued

Select Medical Holdings Corporation Declares Cash Dividend, Payable on or About September 2, 2022

Now 24% undervalued

Second quarter 2022 earnings released: EPS: US$0.43 (vs US$1.22 in 2Q 2021)

Select Medical Holdings Corporation to Report Q2, 2022 Results on Aug 04, 2022

Upcoming dividend of US$0.13 per share

First quarter 2022 earnings released: EPS: US$0.37 (vs US$0.82 in 1Q 2021)

Select Medical Holdings Corporation Announces Cash Dividend, Payable on or About June 1, 2022

Select Medical Holdings Corporation to Report Q1, 2022 Results on May 05, 2022

Select Medical Holdings Corporation (NYSE:SEM) acquired Six Critical Illness Recovery Hospitals.

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Select Medical Holdings Corporation Provides Revenue Guidance for the Year 2022

Investor sentiment deteriorated over the past week

Select Medical Holdings Corporation Provides Earnings Guidance for the Year Ended December 31, 2021

Third quarter 2021 earnings released: EPS US$0.57 (vs US$0.57 in 3Q 2020)

Independent Director recently sold €308k worth of stock

Upcoming dividend of US$0.13 per share

Second quarter 2021 earnings released: EPS US$1.22 (vs US$0.39 in 2Q 2020)

Select Medical Holdings Corporation Provides Earnings Outlook for the Full Year 2021

Select Medical Holdings Corporation (NYSE:SEM) completed the acquisition of AcuityHealthcare, LP.

Select Medical Holdings Corporation (NYSE:SEM) and Northwest Healthcare agreed to acquire Curahealth Tucson from Curahealth, LLC.

Independent Director recently sold €349k worth of stock

Insider recently sold €163k worth of stock